---
categories: 
- Database
- Release
date: 2025-10-02
title: Database release
github_url: https://github.com/vanallenlab/moalmanac-db/releases/tag/v.2025-10-02
---
This release contains updates to the current and draft versions of the database with FDA and EMA precision oncology approvals from September 2025. 

## Database content updates
Added entries:
- (FDA) Dordaviprone for the treatment of adult and pediatric patients with H3-3A:c.83A>T p.K28M (K27M) diffuse midline glioma.
- (FDA) Imlunestrant for treatment of patients with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer **(in development version only)**.
- (EMA) Vorasidenib for the treatment of patients with astrocytoma or oligodendroglioma with an IDH1 R132 or IDH2 R172 mutation **(in development version only)**.
- (EMA) Added document records for Itovebi (inavolisib) and Ziihera (zanidatamab) **(in development version only)**.

Revised entries:
- (FDA) Four statements derived from FDA approvals for Akeega were associated with incorrect biomarkers instead of germline and somatic _BRCA1/2_.
- (FDA) The citation and implication for sunvozertinib and EGFR exon 20 insertions were incorrectly listed.
- Three codings incorrectly pointed to an incorrect url **(in development version only)**.
- The following genes were missing RefSeq mappings and location extensions: _ATR_, _FANCA_, _KMT2A_, _MLH1_, _MRE11_, _NBN_, _TSC1_, _TSC2_, **(in development version only)**.
